← All candidates
One insider buy in the last year — $20.1K in all.
32 filings on record.
APVOAptevo Therapeutics Inc.
NasdaqCM · Healthcare · $3.34M
$1.82
-5.00% · Sep 15
One insider buy in the last year — $20.1K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy◆ 6 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 5×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what APVO ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.34M
Float
1.7M
94% public
Short % float
Pro
Price / profit
0.0
Price / future profit
—
Price / sales
—
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Grant Grady III
Bought $20.1K on Nov 10 — 13,513 sh @ $1.49, held direct, 100% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
18 more transactions on Pro →Context
Wall St
$21.00 avg target
+1053.8% vs today · 1 analyst · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 3 quarters beat
Q2 '26−$5.31 act+$0.89
Q1 '26−$6.41 act−$0.81
Q3 '25−$40.14 act−$2.52
Coverage
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AMLInvestorsHub · 1w agoAll You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to BuyZacks · 05-20Aptevo Therapeutics (APVO) Upgraded to Buy: Here's WhyZacks · 04-10Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks · 11-19
The file stays open
32 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice